BioCryst Pharma Revenue, Profits - BCRX Quarterly Income Statement

Add to My Stocks
$7.32 $0.04 (0.55%) BCRX stock closing price Sep 24, 2018 (Closing)

Stock analysis based on fundamentals means looking at financial statements in addition to the BioCryst Pharma stock price. The income statement gives the investor an understanding of the topline or revenue and bottomline or profit numbers of the company and helps investors evaluate if a company has been growing or not. The income statement for BCRX which shows a YOY revenue growth of 213.82% is specific to a period of time. Investors typically check YoY or QoQ revenue growth. Along with BioCryst Pharma assets and BioCryst Pharma free cash flow, BioCryst Pharma profits as shown in profit and loss statement give key insights about the business. The net profit for 2018 Q2 is $-18.45M and the 2018 Q2 revenue is $12.49M.

View and download details of revenue and profits for BioCryst Pharma for latest & last 40 quarters.
show more
Quarterly
Annual
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
BioCryst Pharma Revenues or Net Sales
12.49M3.98M3.89M8.76M3.1M9.44M8.98M7.76M4.79M4.82M
Cost Of Goods Sold (COGS)---1.14M--2.29M---
BioCryst Pharma Gross Profit
12.49M3.97M3.91M7.61M3.09M9.43M6.69M7.76M4.78M4.82M
Research & Development Expense21.01M18.44M16.94M17.5M15.75M16.77M12.17M14.1M14.16M20.57M
Selling General & Admin Expense9.73M7.74M4.84M3.45M2.85M3.35M2.73M2.89M2.75M3.28M
Income Before Depreciation Depletion Amortization-18.25M-22.21M-17.88M-13.34M-15.51M-10.68M-8.19M-9.24M-12.13M-19.04M
Depreciation Depletion Amortization----------
Non Operating Income2M-1.34M----1.43M5.81M-0.82M-2.73M-2.31M
Interest Expense2.19M2.22M2.23M2.14M2.09M2.1M2.13M1.46M1.42M1.47M
BioCryst Pharma Pretax Income
-18.44M-25.77M-19.56M-15.13M-16.88M-14.21M-4.51M-11.52M-16.28M-22.83M
Provision for Income Taxes----------
MinorityInterest----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-18.45M-25.78M-19.54M-15.13M-16.89M-14.22M-4.5M-11.53M-16.28M-22.83M
Extraordinary Items & Discontinued Operations----------
BioCryst Pharma Profit/ Loss (Net Income)
-18.45M-25.78M-19.54M-15.13M-16.89M-14.22M-4.5M-11.53M-16.28M-22.83M
Average Shares used to compute Diluted EPS98.79M98.59M98.4M83.57M80.42M75.17M73.76M73.73M73.7M73.6M
Average Shares used to compute Basic EPS98.79M98.59M98.4M83.57M80.42M75.17M73.76M73.73M73.7M73.6M
Income Before Nonrecurring Items-18.45M-25.78M-19.54M-15.13M-16.89M-14.22M-4.5M-11.53M-16.28M-22.83M
Income from Nonrecurring Items----------
BioCryst Pharma Earnings Per Share Basic Net
-0.19-0.26-0.20-0.18-0.21-0.19-0.06-0.16-0.22-0.31
BioCryst Pharma Earnings Per Share Diluted Net
-0.19-0.26-0.20-0.18-0.21-0.19-0.06-0.16-0.22-0.31
EPS Diluted Before Nonrecurring Items-0.19-0.26-0.20-0.18-0.21-0.19-0.06-0.16-0.22-0.31
Preferred Dividends Acc Pd----------
Dividends Common0.000.000.00-------
Dividend Per Share Common0.000.000.000.000.000.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Click here to view our BioCryst Pharma financial analysis

The key things to look for in an income statement while doing BioCryst Pharma stock analysis are:

  • Revenue: The money received by selling of goods or services comes under this line item. A QoQ growth - See: BioCryst Pharma revenue chart, implies that the company is growing. It has been the case with BioCryst Pharma. One must look at stocks with increasing revenues, and stay away from stocks whose revenues or sales are declining.
  • Bottom line: This refers to the last line in a profit and loss statement and denotes the net profit or loss for a particular period. The figure currently stands at $-18.45M for BioCryst Pharma for 2018 Q2. This figure is arrived at after deducting all operating expenses, interest, and taxes from revenue.

The income statement is also called statement of revenue and expense. The BCRX financials along with BioCryst Pharma historical stock prices provide a lot of details about the firm.

BioCryst Pharma Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
24.83
Dividend Yield
0%